These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

469 related items for PubMed ID: 12100935

  • 1. Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?
    Labrie F, Candas B, Gomez JL, Cusan L.
    Urology; 2002 Jul; 60(1):115-9. PubMed ID: 12100935
    [Abstract] [Full Text] [Related]

  • 2. Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients.
    Leibowitz RL, Tucker SJ.
    Oncologist; 2001 Jul; 6(2):177-82. PubMed ID: 11306729
    [Abstract] [Full Text] [Related]

  • 3. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
    Soga N, Arima K, Sugimura Y.
    Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy?
    Sarosdy MF, Schellhammer PF, Johnson R, Carroll K, Kolvenbag GJ.
    Urology; 2000 Mar; 55(3):391-5; discussion 395-6. PubMed ID: 10699617
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
    Sato N, Akakura K, Isaka S, Nakatsu H, Tanaka M, Ito H, Masai M, Chiba Prostate Study Group.
    Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group.
    Soloway MS, Schellhammer P, Sharifi R, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G.
    Eur Urol; 1996 Aug; 29 Suppl 2():105-9. PubMed ID: 8717471
    [Abstract] [Full Text] [Related]

  • 14. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
    Soga N, Onishi T, Arima K, Sugimura Y.
    Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
    [Abstract] [Full Text] [Related]

  • 15. [Intermittent androgen deprivation treatment of prostate cancer restarted at low level of serum prostate specific antigen: a pilot study].
    Maekawa S, Maegawa M, Ushida H, Inoue K, Kaneko Y, Ohmori K, Nishimura K.
    Hinyokika Kiyo; 2001 Aug; 47(8):553-5. PubMed ID: 11579594
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival.
    Akaza H, Hinotsu S, Usami M, Arai Y, Kanetake H, Naito S, Hirao Y, Study Group for the Combined Androgen Blockade Therapy of Prostate Cancer.
    Cancer; 2009 Aug 01; 115(15):3437-45. PubMed ID: 19536889
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.